Hostname: page-component-77c89778f8-fv566 Total loading time: 0 Render date: 2024-07-18T11:51:42.227Z Has data issue: false hasContentIssue false
  • English
  • Français

P-201 - Effectiveness of Quetiapine xr Vs. Sertraline in Acute Bipolar Depression as Add-on Therapy to Previous Mood Stabilizer Treatment: a Pilot Study

Published online by Cambridge University Press:  15 April 2020

E. Prieto ,
R. Vázquez-Noguerol ,
M. Franco ,
J. Artal ,
Á.L. Montejo  and
A. González-Pinto
E. Prieto
Affiliation:
Neurosciences, AstraZeneca Spain, Madrid
R. Vázquez-Noguerol
Affiliation:
Psychiatry, Hospital de Rebullón, Vigo
M. Franco
Affiliation:
Psychiatry, Hospital Provincial, Zamora
J. Artal
Affiliation:
Psychiatry, Hospital Marqués de Valdecilla, Santander
Á.L. Montejo
Affiliation:
Psychiatry, CSM Alamedilla, Salamanca
A. González-Pinto
Affiliation:
Psychiatry, Hospital Santiago Apóstol, Vitoria, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction:

Even at therapeutic doses, mood stabilizers do not completely address symptoms in bipolar depression. Some guidelines recommend add-on antidepressant therapy or quetiapine.

Objectives:

Early effectiveness of quetiapine extended release (quetiapine XR) vs. sertraline in adults with bipolar depression; treated with lithium or valproate at clinically therapeutic blood levels (change from baseline in the MADRS global score at week 2 (LOCF) endpoint). Others (secondary objectives) were measured at week 8.

Methods:

Prospective, open label, randomized study of 8 weeks follow-up (D1443L00058).

Results:

27 patients were randomized to quetiapine XR (14) or sertraline (13). Mean age was 46.07 years. 17 patients (62.96%) were male. 20 (74.07%) were diagnosed with bipolar disorder type I. Mean number of previous events were 9.74. Mean baseline MADRS score was 28.23 (SD 5.86) and 29.50 (SD 5.00) for sertraline and quetiapine XR groups, respectively (p = 0.59).

Mean change in MADRS score (2 weeks from baseline) was: -6.62 (sertraline group) and -13.14 (quetiapine XR group) (p = 0.08). Final change from baseline was: -10.62 (sertraline) and -17.14 (quetiapine XR) (p = 0.1). Patients with at least one AE and one AE leading to study withdrawal were 12 and 3, respectively (quetiapine XR group); and 9 and 2, respectively (sertraline group). the most frequent AEs were somnolence, dry mouth (35.7%, 21.4%, respectively) (quetiapine XR group), and insomnia, diarrhea, dyspepsia (14.3% for each one) (sertraline group).

Conclusions:

Numeric differences (though not significant) in favour of quetiapine XR exist for the early effectiveness of quetiapine XR in bipolar depression. Sponsorship by AstraZeneca.

Type
Abstract
Information
European Psychiatry , Volume 27 , Issue S1: Abstracts of the 20th European Congress of Psychiatry , 2012 , pp. 1
Copyright
Copyright © European Psychiatric Association 2012
Submit a response

Comments

No Comments have been published for this article.